Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524025 · ClinicalTrials.gov registry record
The SPOT-HPV Study
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 360
- Enrollment target
NCT05524025: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT05524025 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 360 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05524025 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
Study Summary
The purpose of this research is to evaluate a new test for oral HPV DNA in saliva ('oral rinse test').
Primary Outcome
Percentage of controls without cancer compared with percentage of cancer patients who have TTMV-HPV DNA detected in their saliva
Interventions
- DIAGNOSTIC_TEST Salivary TTMV-HPV DNA Test
- DIAGNOSTIC_TEST Blood TTMV-HPV DNA Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2026-01-01 |
What the finished NCT05524025 record still lists
NCT05524025 is an observational study that tracks outcomes without assigning an intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Salivary TTMV-HPV DNA Test is the first listed.
NCT05524025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05524025 about?
NCT05524025 is a clinical study titled "The SPOT-HPV Study". The purpose of this research is to evaluate a new test for oral HPV DNA in saliva ('oral rinse test').
What is the current status of trial NCT05524025?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2022-11-30. Estimated completion is 2026-01-01.
What interventions are being tested in trial NCT05524025?
The interventions under investigation include: Salivary TTMV-HPV DNA Test (DIAGNOSTIC_TEST), Blood TTMV-HPV DNA Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05524025?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI